Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.119.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.25.2 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.25.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.25.2 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.122.6 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.122.6 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.122.6 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.621.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.621.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.621.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.39.2 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.39.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.39.2 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.125 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.125 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.125 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.103.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.103.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.103.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.92 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.92 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.92 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.122.4 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.122.4 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.122.4 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.101 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.101 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.101 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.1.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.1.14NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.14NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.14NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.57NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.57NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.57NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.49NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.49NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.49NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BE.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BE.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BE.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.4.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.4.8NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.9.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.9.6NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.9.6NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used